10-Q: Lyell Immunopharma Reports Q2 2024 Results, Provides Clinical Trial Updates

Lyell Immunopharma's Q2 2024 report details ongoing clinical trials, financial results, and strategic updates, including progress in their cell therapy programs.

Summary

• Lyell Immunopharma, a clinical-stage cell therapy company, reported a net loss of $45.8 million for the three months ended June 30, 2024, and $106.5 million for the six months ended June 30, 2024.
• The company's research and development expenses were $40.3 million for the three months and $83.4 million for the six months ended June 30, 2024.
• General and administrative expenses were $12.3 million for the three months and $25.8 million for the six months ended June 30, 2024.
• As of June 30, 2024, Lyell had $491.1 million in cash, cash equivalents, and marketable securities.
• The company believes its current resources will fund operations into 2027.
• Lyell is advancing multiple product candidates, including LYL797, LYL845, and LYL119, through clinical trials.
• Initial data from the LYL797 Phase 1 trial showed a 40% objective response rate in a subset of TNBC patients at the 150 x 10^6 cell dose level.
• The company expects to initiate a second Phase 1 clinical trial of LYL797 for hematologic indications in the second half of 2024.
• LYL119 is entering Phase 1 clinical trials in patients with solid tumors in the second half of 2024.
• LYL845 is in Phase 1 clinical development, with initial data expected in the second half of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical trial updates and a strong cash position, the significant net losses and the need for future capital raises temper the overall sentiment. The company is making progress but faces significant challenges.

Positives

• Lyell has a strong cash position of $491.1 million, which is expected to fund operations into 2027.
• The company achieved a 100% manufacturing success rate for LYL797.
• Initial clinical data for LYL797 showed promising anti-tumor activity, with a 40% objective response rate in a subset of TNBC patients.
• LYL797 CAR T cells demonstrated expansion in peripheral blood and infiltration into solid tumors.
• The company is advancing multiple product candidates into clinical trials, including LYL119 entering Phase 1 in the second half of 2024.

Negatives

• Lyell reported a significant net loss of $45.8 million for the three months ended June 30, 2024.
• The company experienced a decrease in cash and cash equivalents from $145.6 million at the end of 2023 to $133.4 million as of June 30, 2024.
• The Phase 1 trial of LYL797 reported adverse events, including pneumonitis, which led to a separation of dose escalation into two cohorts based on lung involvement.
• The company has incurred significant operating losses since its inception and expects to continue to incur substantial losses for the foreseeable future.

Risks

• The company is early in its research and clinical development efforts, and there is no guarantee of successful product development or commercialization.
• Clinical trials are subject to delays and may not produce positive results.
• The company faces substantial competition in the biotechnology and pharmaceutical industries.
• The manufacturing of cell therapies is complex and subject to various risks, including supply chain issues.
• The company relies on third parties for research, clinical trials, and manufacturing, which introduces risks related to their performance.
• The company's success payment obligations may result in dilution to stockholders or a drain on cash resources.
• Unstable market and economic conditions may have adverse consequences on the company's business and stock price.
• The company may not be able to obtain or maintain sufficient intellectual property protection for its product candidates.

Future Outlook

Lyell believes its existing cash, cash equivalents, and marketable securities will be sufficient to meet its working capital and capital expenditure needs into 2027. The company anticipates needing to raise additional capital in the future to fund operations, including further development of product candidates and commercialization.

Management Comments

• The company is focused on advancing its pipeline of product candidates enhanced with proprietary anti-exhaustion technologies.
• Lyell views its manufacturing team and capabilities as a significant competitive advantage.
• The company is evaluating third-party manufacturing options as part of an overall CAR T-cell manufacturing strategy to build scale and reduce cost.

Industry Context

Lyell is operating in the competitive cell therapy space, focusing on novel approaches to address T-cell exhaustion and improve outcomes for solid tumor patients. The company's focus on genetic and epigenetic reprogramming technologies aligns with the industry's push for more effective and durable cell therapies.

Comparison to Industry Standards

• Lyell's 40% objective response rate in a subset of TNBC patients in the LYL797 trial is a notable result in the context of solid tumor CAR T-cell therapy, where response rates have historically been lower than in hematological malignancies. This compares favorably to some early-stage trials of other CAR T-cell therapies in solid tumors.
• The company's focus on anti-exhaustion technologies, such as c-Jun overexpression and EpiR, is a key differentiator, as T-cell exhaustion is a major challenge in solid tumor cell therapy. This approach is similar to other companies exploring novel methods to enhance T-cell persistence and efficacy.
• Lyell's investment in its own manufacturing facility is a strategic move to control supply chain and optimize production, which is a common challenge for cell therapy companies. This is similar to other companies that have invested in in-house manufacturing capabilities to ensure quality and scalability.
• The company's approach to TIL therapy with LYL845, incorporating epigenetic reprogramming, is aimed at improving the polyclonality and stem-like qualities of TILs, which is a common goal in the TIL therapy field. This is comparable to other companies exploring methods to enhance TIL efficacy.
• The company's pipeline, including LYL797, LYL845, and LYL119, targets indications with high unmet needs, such as TNBC, NSCLC, ovarian cancer, and endometrial cancer, which are also areas of focus for other companies in the cell therapy space.

Corporate Governance

Related Party Transactions

• The company has a sublease agreement with Sonoma Biotherapeutics, Inc., a related party, for approximately 18,000 square feet of space in South San Francisco.

Stakeholder Impact

• Shareholders may experience dilution due to potential future capital raises.
• Employees may be affected by the company's financial performance and strategic decisions.
• Patients may benefit from the development of new cell therapies.
• Suppliers and partners may be impacted by the company's financial condition and operational decisions.

Next Steps

• The company expects to initiate a second Phase 1 clinical trial of LYL797 for hematologic indications in the second half of 2024.
• LYL119 is entering Phase 1 clinical trials in patients with solid tumors in the second half of 2024.
• Initial clinical and translational data from the Phase 1 trial of LYL845 in patients with advanced melanoma are expected in the second half of 2024.
• Updated data from the ongoing Phase 1 trial of LYL797 in solid tumor indications, including the initiation of dose expansion, are expected in late 2024 to early 2025.

Key Dates

Keywords

cell therapy, immunotherapy, CAR T-cell, TIL, LYL797, LYL845, LYL119, clinical trial, ROR1, T-cell exhaustion, cancer, oncology, biotechnology, manufacturing, EpiR, c-Jun, NR4A3 knockout, StimR